Institutional development · Teaching, learning and curriculum · Germany
Ulm University launches biotech master's linking RNA and stem cell therapies with AI
Ulm University in Germany has introduced a master's programme in Pharmaceutical and Molecular Biotechnology that combines pharmaceutical research with modern therapeutic approaches and data science.
Why it matters: Students considering a master's at Ulm University can now choose a programme spanning molecular biology, pharmacy and data-driven biotechnology.
Ulm University said it has launched a new master's programme in Pharmaceutical and Molecular Biotechnology, abbreviated PMB.
According to the university, students on the course learn how RNA-, protein- and stem cell-based therapies work.
The university said the programme also covers how bioinformatics and artificial intelligence methods can be applied to developing new pharmaceutical active substances.
Ulm University describes the course as sitting where molecular biology, pharmacy and data-driven biotechnology meet.
Editor’s view
Sarah Williamson, Teaching, Digital and AI Editor
Students at Ulm University who choose the new PMB master's will study therapy-focused biotechnology alongside bioinformatics and AI methods for developing pharmaceutical active substances.
